Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency

10 Jul 2020

Abstract excerpt

Poly(ADP ribose) polymerase inhibitors (PARPi) have efficacy in triple negative breast (TNBC) and ovarian cancers (OCs) harboring BRCA mutations, generating homologous recombination deficiencies (HRDs). DNA methyltransferase inhibitors (DNMTi) increase PARP trapping and reprogram the DNA damage response to generate HRD, sensitizing BRCA-proficient cancers to PARPi. We now define the mechanisms through which HRD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Immune Cell Function and Interaction
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32651270
DOI: 10.1073/pnas.2003499117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiencyPMID 32651270Read ↗

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancersSemantic proximity Read ↗

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentSemantic proximity Read ↗

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translationSemantic proximity Read ↗

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer typesSemantic proximity Read ↗

Beyond BRCA: Discovery of novel causes and consequences of homologous recombination deficienciesSemantic proximity Read ↗

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancerSemantic proximity Read ↗

Genomic and molecular landscape of homologous recombination deficiency across multiple cancer typesSemantic proximity Read ↗

The DNA damage induced immune response: Implications for cancer therapySemantic proximity Read ↗

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerSemantic proximity Read ↗

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune CheckpointsSemantic proximity Read ↗

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsSemantic proximity Read ↗

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.